Xenetic Biosciences, Inc.

menu

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Technology
    • Overview
    • DNase Platform
    • XCART™ Platform
    • PolyXen®
    • Publications
  • Product Pipeline
    • Overview
    • DNase
    • XCART™
    • PolyXen®
  • News & Media
    • Press Releases
    • Presentations
    • Multimedia
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Information
    • Financials
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Proxy Materials
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

Jun 2, 2022

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

Apr 27, 2022

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

Mar 23, 2022

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 12, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Sep 9, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 8, 2021

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Aug 13, 2021

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

Jul 28, 2021

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...13
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2023Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap